Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation

Transplant International

Volumn 27, Issue 2, 2014, Pages 187-196

  Barnett, A Nicholas R ^a,b   Manook, Miriam ^a,b   Nagendran, Myura ^a   Kenchayikoppad, Shivakumar ^a   Vaughan, Robert ^a,b,c   Dorling, Anthony ^a,b   Hadjianastassiou, Vassilis G ^a,b,d   Mamode, Nizam ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GSTS Pathology   (United Kingdom)

^d NICOSIA GENERAL HOSPITAL   (Cyprus)

Author keywords

ABO incompatibility; immunoadsorption; kidney transplantation; monoclonal antibodies; plasmapheresis

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BLOOD GROUP A ANTIBODY; BLOOD GROUP ANTIBODY; BLOOD GROUP B ANTIBODY; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; AGED; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; BONE MARROW BIOPSY; CANCER RECURRENCE; CAUSE OF DEATH; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESENSITIZATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; GLIOBLASTOMA; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; HYPOTHESIS; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVING DONOR; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; PATIENT HISTORY OF KIDNEY TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; SEPSIS; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; VULVA CARCINOMA;

ABO INCOMPATIBILITY; IMMUNOADSORPTION; KIDNEY TRANSPLANTATION; MONOCLONAL ANTIBODIES; PLASMAPHERESIS;

ABO BLOOD-GROUP SYSTEM; ADSORPTION; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD GROUP INCOMPATIBILITY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84892187436     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12234     Document Type: Article

References (50)

1. Alexandre GP, Squifflet JP, De Bruyere M, et al,. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transpl Proc 1987; 19: 4538.
2. Sawada T, Fuchinoue S, Teraoka S,. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207.
3. Tyden G, Kumlien G, Fehrman I,. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730.
4. Sonnenday CJ, Warren DS, Cooper M, et al,. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
5. Gloor JM, Lager DJ, Fidler ME, et al,. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 1572.
6. Saito K, Nakagawa Y, Suwa M, et al,. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006; 13: 111.
7. Chikaraishi T, Sasaki H, Tsutsumi H, et al,. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab. Transpl Proc 2008; 40: 3445.
8. Galliford J, Charif R, Chan KK, et al,. ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation 2008; 86: 901.
9. Haidinger M, Schmaldienst S, Kormoczi G, et al,. Vienna experience of ABO-incompatible living-donor kidneytransplantation. Wien Klin Wochenschr 2009; 121: 247.
10. Oettl T, Halter J, Bachmann A, et al,. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant 2009; 24: 298.
11. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T,. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61.
12. Schousboe K, Titlestad K, Baudier F, Hansen LU, Bistrup C,. ABO-incompatible kidney transplantation. Dan Med Bull 2010; 57: A4197.
13. Wilpert J, Fischer K-G, Pisarski P, et al,. Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. Nephrol Dial Transplant 2010; 25: 3778.
14. Habicht A, Broker V, Blume C, et al,. Increase of infectious complications in ABO-incompatible kidney transplant recipients-a single centre experience. Nephrol Dial Transplant 2011; 26: 4124.
15. Genberg H, Kumlien G, Wennberg L, Tyden G,. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2011; 26: 2394.
16. Shirakawa H, Ishida H, Shimizu T, et al,. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011; 25: 878.
17. Fuchinoue S, Ishii Y, Sawada T, et al,. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91: 853.
18. Chung BH, Lee JY, Kang SH, et al,. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail 2011; 33: 150.
19. Yoshimura N, Ushigome H, Matsuyama M, et al,. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment. Transpl Proc 2012; 44: 140.
20. Toki D, Ishida H, Setoguchi K, et al,. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9: 567.
21. Montgomery RA, Locke JE, King KE, et al,. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246.
22. Flint SM, Walker RG, Hogan C, et al,. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11: 1016.
23. Wilpert J, Geyer M, Pisarski P, et al,. On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorptions after ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2007; 22: 3048.
24. Morath C, Becker LE, Leo A, et al,. ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012; 93: 827.
25. Renner FC, Czekalinska B, Kemkes-Matthes B, et al,. Postoperative bleeding after ABO-incompatible living donor kidney transplantation. Transpl Proc 2010; 42: 4164.
26. Yeh JH, Chiu HC,. Coagulation abnormalities in serial double-filtration plasmapheresis. J Clin Apher 2001; 16: 139.
27. Racusen LC, Solez K, Colvin RB, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
28. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
29. Campbell M,. Statistics at Square Two: Understanding Modern Statistical Applications in Medicine. London: BMJ Books, 2001, 59-73.
30. Thomas S, Vivancos R, Corless C, Wood G, Beeching NJ, Beadsworth MB,. Increasing frequency of Pneumocystis jirovecii pneumonia in renal transplant recipients in the United Kingdom: clonal variability, clusters, and geographic location. Clin Infect Dis 2011; 53: 307.
31. Kumar D, Gourishankar S, Mueller T, et al,. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009; 11: 167.
32. Shelton E, Yong M, Cohney S,. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009; 14: 696.
33. Rostaing L, Guilbeau-Frugier C, Kamar N,. Rituximab for humoral rejection after kidney transplantation: an update. Transplantation 2009; 87: 1261.
34. Kamar N, Milioto O, Puissant-Lubrano B, et al,. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10: 89.
35. Drage M, Hadjianastassiou V, Dorling A, Mamode N,. Rituximab may not lead to increased infection rates in transplant recipients. Am J Transplant 2010; 10: 2723.
36. Scemla A, Loupy A, Candon S, et al,. Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study. Transplantation 2010; 90: 1180.
37. Vo AA, Lukovsky M, Toyoda M, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
38. Nishida H, Ishida H, Tanaka T, et al,. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy. Transpl Int 2009; 22: 961.
39. Kahwaji J, Sinha A, Toyoda M, et al,. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894.
40. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K,. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466.
41. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM,. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 2008; 8: 2607.
42. Tyden G, Genberg H, Tollemar J, et al,. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325.
43. van den Hoogen MWF, Hilbrands LB,. More on B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 361: 1215.
44. Norden G, Briggs D, Cockwell P, et al,. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplantation 2006; 13: 148.
45. Lawrence C, Galliford JW, Willicombe MK, et al,. Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is therapeutic? Transplantation 2011; 92: 1129.
46. Barnett ANR, Hadjianastassiou VG, Mamode N,. Rituximab in renal transplantation. Transpl Int 2013; 26: 563.
47. Welsh KI, Vandam M, Koffman CG, et al,. Transplantation of blood-group A2 kidneys into O-recipient or B-recipients-the effect of pretransplant anti-A titers on graft-survival. Transpl Proc 1987; 19: 4565.
48. Kumlien G, Wilpert J, Safwenberg J, Tyden G,. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation 2007; 84: S17.
49. Barnett ANR, Hudson A, Hadjianastassiou VG, et al,. Distribution of ABO blood group antibody titers in pediatric patients awaiting renal transplantation: implications for organ allocation policy. Transplantation 2012; 94: 362.
50. Clatworthy M, Watson C, Allison M, Dark J,. Transplantation at a Glance. Chichester: Wiley-Blackwell, 2012.